John C. Taylor

John C. Taylor

Auto-generated profile, based on publicly available information

John C. Taylor

Pathology and Data Analytics, Leeds Institute for Medical Research at St James's, University of Leeds, UK; Leeds Institute for Data Analytics, University of Leeds, UK

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2019 in BMJ
Verified
Journal Article
Open access
PDF file
NBNicholas E Burr
Nicholas E Burr
EDEdmund Derbyshire
Edmund Derbyshire
JTJohn Taylor
John Taylor
SWSimon Whalley
Simon Whalley
VSVenkataraman Subramanian
Venkataraman Subramanian
EMEva J A Morris
Eva J A Morris
Objectives To quantify post-colonoscopy colorectal cancer (PCCRC) rates in England by using recent World Endoscopy Organisation guidelines, compare incidence among colonoscopy providers, and explore associated factors that could benefit from quality improvement initiatives. Design Population based cohort study. Setting National Health Service in England between 2005 and 2013. Population All people undergoing colonoscopy and subsequently diagnosed as having colorectal cancer up to three years after their investigation (PCCRC-3yr). Main outcome measures National trends in incidence of PCCRC (within 6-36 months of colonoscopy), univariable and multivariable analyses to explore factors associated with occurrence, and funnel plots to measure variation among providers. Results The overall unadjusted PCCRC-3yr rate was 7.4% (9317/126 152), which decreased from 9.0% in 2005 to 6.5% in 2013 (P<0.01). Rates were lower for colonoscopies performed under the NHS bowel cancer screening programme (593/16 640, 3.6%), while they were higher for those conducted by non-NHS providers (187/2009, 9.3%). Rates were higher in women, in older age groups, and in people with inflammatory bowel disease or diverticular disease, in those with higher comorbidity scores, and in people with previous cancers. Substantial variation in rates among colonoscopy providers remained after adjustment for case mix. Conclusions Wide variation exists in PCCRC-3yr rates across NHS colonoscopy providers in England. The lowest incidence was seen in colonoscopies performed under the NHS bowel cancer screening programme. Quality improvement initiatives are needed to address this variation in rates and prevent colorectal cancer by enabling earlier diagnosis, removing premalignant polyps, and therefore improving outcomes.

14 November 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
DDDavid L. Duffy
David L. Duffy
GZGu Zhu
Gu Zhu
XLXin Li
Xin Li
MSMarianna Sanna
Marianna Sanna
MIMark M. Iles
Mark M. Iles
NMNicholas G. Martin
Nicholas G. Martin
The total number of acquired melanocytic nevi on the skin is strongly correlated with melanoma risk. Here we report a meta-analysis of 11 nevus GWAS from Australia, Netherlands, UK, and USA comprising 52,506 individuals. We confirm known loci including MTAP, PLA2G6, and IRF4, and detect novel SNPs in KITLG and a region of 9q32. In a bivariate analysis combining the nevus results with a recent melanoma GWAS meta-analysis (12,874 cases, 23,203 controls), SNPs near GPRC5A, CYP1B1, PPARGC1B, HDAC4, FAM208B, DOCK8, and SYNE2 reached global significance, and other loci, including MIR146A and OBFC1, reached a suggestive level. Overall, we conclude that most nevus genes affect melanoma risk (KITLG an exception), while many melanoma risk loci do not alter nevus count. For example, variants in TERC and OBFC1 affect both traits, but other telomere length maintenance genes seem to affect melanoma risk only. Our findings implicate multiple pathways in nevogenesis.

1 June 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
JCJiyeon Choi
Jiyeon Choi
TZTongwu Zhang
Tongwu Zhang
AVAndrew Vu
Andrew Vu
JAJulien Ablain
Julien Ablain
MMMatthew M. Makowski
Matthew M. Makowski
KBKevin M. Brown
Kevin M. Brown
Genome-wide association studies (GWAS) have identified ~20 melanoma susceptibility loci, most of which are not functionally characterized. Here we report an approach integrating massively-parallel reporter assays (MPRA) with cell-type-specific epigenome and expression quantitative trait loci (eQTL) to identify susceptibility genes/variants from multiple GWAS loci. From 832 high-LD variants, we identify 39 candidate functional variants from 14 loci displaying allelic transcriptional activity, a subset of which corroborates four colocalizing melanocytecis-eQTL genes. Among these, we further characterize the locus encompassing the HIV-1 restriction gene,MX2(Chr21q22.3), and validate a functional intronic variant, rs398206. rs398206 mediates the binding of the transcription factor, YY1, to increaseMX2levels, consistent with thecis-eQTL ofMX2in primary human melanocytes. Melanocyte-specific expression of humanMX2in a zebrafish model demonstrates accelerated melanoma formation in aBRAFV600Ebackground. Our integrative approach streamlines GWAS follow-up studies and highlights a pleiotropic function ofMX2in melanoma susceptibility.

25 May 2018 in The Pharmacogenomics Journal
Verified
Journal Article
Closed access
PDF file
OMOn Behalf Of The Matura
On Behalf Of The Matura
JTJohn C. Taylor
John C. Taylor
APAnd Pamera
And Pamera
COConsortia
Consortia
TBTim Bongartz
Tim Bongartz
JBJennifer H. Barrett
Jennifer H. Barrett

30 July 2015 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
SMSarah Louise Mackie
Sarah Louise Mackie
JTJohn C. Taylor
John C. Taylor
LHLubna Haroon-Rashid
Lubna Haroon-Rashid
SMStephen Martin
Stephen Martin
BDBhaskar Dasgupta
Bhaskar Dasgupta
AMAnn W. Morgan
Ann W. Morgan
Introduction: Giant cell arteritis (GCA) is an autoimmune disease commonest in Northern Europe and Scandinavia. Previous studies report various associations with HLA-DRB1*04 and HLA-DRB1*01; HLA-DRB1 alleles show a gradient in population prevalence within Europe. Our aims were (1) to determine which amino acid residues within HLA-DRB1 best explained HLA-DRB1 allele susceptibility and protective effects in GCA, seen in UK data combined in meta-analysis with previously published data, and (2) to determine whether the incidence of GCA in different countries is associated with the population prevalence of the HLA-DRB1 alleles that we identified in our meta-analysis. Methods: GCA patients from the UK GCA Consortium were genotyped by using single-strand oligonucleotide polymerization, allele-specific polymerase chain reaction, and direct sequencing. Meta-analysis was used to compare and combine our results with published data, and public databases were used to identify amino acid residues that may explain observed susceptibility/protective effects. Finally, we determined the relationship of HLA-DRB1*04 population carrier frequency and latitude to GCA incidence reported in different countries. Results: In our UK data (225 cases and 1378 controls), HLA-DRB1*04 carriage was associated with GCA susceptibility (odds ratio (OR) = 2.69, P = 1.5×10−11), but HLA-DRB1*01 was protective (adjusted OR = 0.55, P = 0.0046). In meta-analysis combined with 14 published studies (an additional 691 cases and 4038 controls), protective effects were seen from HLA-DR2, which comprises HLA-DRB1*15 and HLA-DRB1*16 (OR = 0.65, P = 8.2×10−6) and possibly from HLA-DRB1*01 (OR = 0.73, P = 0.037). GCA incidence (n = 17 countries) was associated with population HLA-DRB1*04 allele frequency (P = 0.008; adjusted R2 = 0.51 on univariable analysis, adjusted R2 = 0.62 after also including latitude); latitude also made an independent contribution. Conclusions: We confirm that HLA-DRB1*04 is a GCA susceptibility allele. The susceptibility data are best explained by amino acid risk residues V, H, and H at positions 11, 13, and 33, contrary to previous suggestions of amino acids in the second hypervariable region. Worldwide, GCA incidence was independently associated both with population frequency of HLA-DRB1*04 and with latitude itself. We conclude that variation in population HLA-DRB1*04 frequency may partly explain variations in GCA incidence and that HLA-DRB1*04 may warrant investigation as a potential prognostic or predictive biomarker.

26 November 2019 in BMJ Open
Verified
Journal Article
Open access
PDF file
JTJohn Taylor
John Taylor
PWPenny Wright
Penny Wright
HRHannah Rossington
Hannah Rossington
JMJackie Mara
Jackie Mara
AGAmy Glover
Amy Glover
PQPhillip Quirke
Phillip Quirke
Introduction Although colorectal cancer outcomes in England are improving, they remain poorer than many comparable countries. Yorkshire Cancer Research has, therefore, established a Bowel Cancer Improvement Programme (YCR BCIP) to improve colorectal cancer outcomes within Yorkshire and Humber, a region representative of the nation. It aims to do this by quantifying variation in practice, engaging with the colorectal multidisciplinary teams (MDTs) to understand this and developing educational interventions to minimise it and improve outcomes. Methods and analysis Initially, routine health datasets will be used to quantify variation in the demographics, management and outcomes of patients across the Yorkshire and Humber region and results presented to MDTs. The YCR BCIP is seeking to supplement these existing data with patient-reported health-related quality of life information (patient-reported outcome measures, PROMs) and tissue sample analysis. Specialty groups (surgery, radiology, pathology, clinical oncology, medical oncology, clinical nurse specialists and anaesthetics) have been established to provide oversight and direction for their clinical area within the programme, to review data and analysis and to develop appropriate educational initiatives. Ethics and dissemination The YCR BCIP is aiming to address the variation in practice to significantly improve colorectal cancer outcomes across the Yorkshire and Humber region. PROMs and tissue sample collection and analysis will help to capture the information required to fully assess care in the region. Engagement of the region’s MDTs with their data will lead to a range of educational initiatives, studies and clinical audits that aim to optimise practice across the region.